Business
Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference
Dr. Steven Quay, Chairman and Chief Executive Officer to participate in Fireside Chat with Emily Bodnar, HCW Biotech Research Analyst SEATTLE, Aug. 28, 2025
About this update from Atossa Therapeutics, Inc.
[{"type":"text","content":"Dr. Steven Quay, Chairman and Chief Executive Officer to participate in Fireside Chat with Emily Bodnar, HCW Biotech Research Analyst\nSEATTLE, Aug. 28, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (\"Atossa\" or the \"Company\"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announced that Dr. Steven Quay, Chairman and Chief Executive Officer, will participate in a fireside chat with biotech research analyst, Emily Bodnar, at the H.C. Wainwright (HCW) 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:00 p.m. ET, at the Lotte New York Palace Hotel in New York City.\n\n \n \n\n \nDr. Quay will provide an update on Atossa's lead program, (Z)-endoxifen, a highly potent Selective Estrogen Receptor Modulator (SERM) with dual mechanisms of action that may offer a differentiated solution for women in both prevention and treatment settings of breast cancer. This includes progress across multiple clinical studies and encouraging feedback recently received by regulatory advisors that could accelerate the Company's path forward.\nThe live presentation will be webcast, with a replay available for approximately 90 days on the Company's investor website: https://investors.atossatherapeutics.com\nIn addition, a 60-second video message from Dr. Quay previewing the presentation is now available here, offering a personal invitation to learn more of Atossa's vision and upcoming catalysts.\nInvestors interested in scheduling meetings with Atossa management may do so through the HCW conference portal, via their HCW representative, or directly by contacting a Company representative.\nAbout Atossa Therapeutics\nAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment and prevention through innovative science and patient-focused solutions. The Company's lead product candidate, (Z)-endoxifen, is being developed as a therapy across the breast cancer spectrum, including prevention and treatment settings. For more information, please visit www.atossatherapeutics.com.\nForward-Looking Statements\nThis press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. W...